Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ( "Nuvectis " or the "Company "), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.

Conference Details:

A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.

The company’s lead drug candidate is ciprocopan, a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact

Kevin Gardner
LifeSci Advisorskgardner@lifesciadvisors.com

© 2026 GlobeNewswire, Inc. All Rights Reserved.

Read More..

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.